Favipiravir
- Generic Name
- Favipiravir
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT04425460
- Locations
- 🇷🇴
"Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania
🇷🇴Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timişoara, Timis, Romania
🇷🇴Emergency County Hospital "Pius Brinzeu"Timisoara, Timişoara, Timis, Romania
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
- Conditions
- Sars-CoV2COVID-19
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Ministry of Health, Turkey
- Target Recruit Count
- 1008
- Registration Number
- NCT04411433
- Locations
- 🇹🇷
Hacettepe University, School of Medicine, Ankara, Turkey
Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions
- Conditions
- Bioequivalence
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- World Medicine ILAC SAN. ve TIC. A.S.
- Target Recruit Count
- 30
- Registration Number
- NCT04407000
- Locations
- 🇹🇷
Novagenix Drug R&D Center, Akyurt, Ankara, Turkey
🇹🇷Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey
Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
- Conditions
- Bioequivalence
- Interventions
- Drug: FAVICOVIR 200 mg Film Tablet
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Atabay Kimya Sanayi Ticaret A.S.
- Target Recruit Count
- 30
- Registration Number
- NCT04406194
- Locations
- 🇹🇷
Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey
🇹🇷Novagenix Drug R&D Center, Akyurt, Ankara, Turkey
Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh
- Conditions
- Favipiravir (Favipira)COVID-19
- Interventions
- Drug: Only Standard Treatment
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Bangladesh Medical Research Council (BMRC)
- Target Recruit Count
- 50
- Registration Number
- NCT04402203
- Locations
- 🇧🇩
Mahanagar General Hospital, Dhaka (Site-1), Mugda Medical College Hospital, Dhaka (Site-2), Kurmitola General Hospital, Dhaka (Site-3), Dhaka Medical College Hospital, Dhaka (Site-4), Dhaka, Bangladesh
Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions
- Conditions
- Bioequivalence
- Interventions
- Drug: FAVIRA 200 MG Film Tablet
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Novelfarma Ilaç San. ve Tic. Ltd. Sti.
- Target Recruit Count
- 30
- Registration Number
- NCT04400682
- Locations
- 🇹🇷
Novagenix Drug R&D Center, Akyurt, Ankara, Turkey
🇹🇷Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey
Favipiravir vs Hydroxychloroquine vs Control in COVID -19
- Conditions
- SARS-CoV 2COVID-19
- Interventions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 150
- Registration Number
- NCT04387760
- Locations
- 🇧🇭
Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain
Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19
- Conditions
- HydroxychloroquineCOVID-19FavipiravirKaletraLopinavir/Ritonavir
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Baqiyatallah Medical Sciences University
- Target Recruit Count
- 40
- Registration Number
- NCT04376814
- Locations
- 🇮🇷
Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of
Early Intervention in COVID-19: Favipiravir Verses Standard Care
- Conditions
- Coronavirus Infection
- Interventions
- Other: Standard of care management
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Chelsea and Westminster NHS Foundation Trust
- Target Recruit Count
- 502
- Registration Number
- NCT04373733
- Locations
- 🇧🇷
Grupo Hospitalar Conceição, Porto Alegre, Brazil
🇲🇽Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico
🇬🇧Hull University Teaching Hospitals NHS Trust - Castle Hill Hospital, Hull, United Kingdom
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04358549
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.